Regeneron Pharmaceuticals Inc. 8-K Report: Key Financial Insights as of January 2025

Here are the key points extracted from the provided financial report excerpt:

Entity Information:

Company Name: Regeneron Pharmaceuticals, Inc.
CIK: 0000872589
SEC File Number: 000-19034
Tax ID: 13-3444607
Address: 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707
Phone Number: 914-847-7000

Filing Type:

Form: 8-K (Current Report)

Filing Date:

As of Date: January 13, 2025

Stock Information:

Common Stock: Par value of $0.001 per share
Stock Ticker: REGN
Exchange: NASDAQ

Financial Reporting:

Unit of Measure:
- Currency: USD (U.S. Dollars)
- Shares: Denoted in shares

Context:

The report is likely providing a snapshot of the company's financial status as of the specified date, January 13, 2025.

Insights:

Importance of Filing: An 8-K report is crucial as it provides shareholders and the public with important information that may affect the company’s stock price and market perception. It typically reports unscheduled material events or corporate changes.
Regeneron's Profile: As a major player in the pharmaceutical industry, the information indicates that the company is actively engaging with the SEC, which is important for transparency and compliance.
Future Reporting Considerations: Given that the report is dated for early 2025, stakeholders may want to consider upcoming developments in Regeneron’s pipeline or market conditions affecting its stock performance.

This analysis highlights the essential details that stakeholders, including investors and analysts, would focus on when evaluating Regeneron Pharmaceuticals, Inc.